A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations

Diabetes and Cancer: A consensus report

(2010) E. Giovannucci et al.   DIABETES CARE

Insulin Pump Therapy in Patients with Type 2 Diabetes Safely Improved Glycemic Control Using a Simple Insulin Dosing Regimen

(2010) Steven V. Edelman et al.   Diabetes Technology & Therapeutics

Growth hormone, the insulin-like growth factor axis, insulin and cancer risk

(2010) Peter E. Clayton et al.   Nature Reviews Endocrinology

In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites

(2010) Mark R. Sommerfeld et al.   PLoS One

Treat early, treat appropriately

(2010) Andreas Liebl et al.   Primary Care Diabetes

Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes

(2009) Marcus Hompesch et al.   CURRENT MEDICAL RESEARCH AND OPINION

Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy

(2009) T. Heise et al.   DIABETES CARE

Obesity does not influence the unique pharmacological properties of different biphasic insulin aspart preparations in patients with type 2 diabetes

(2009) T. Parkner et al.   DIABETES OBESITY & METABOLISM

Combined randomised controlled trial experience of malignancies in studies using insulin glargine

(2009) P. D. Home et al.   DIABETOLOGIA

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study

(2009) J. Rosenstock et al.   DIABETOLOGIA

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

(2009) J. M. Jonasson et al.   DIABETOLOGIA

No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis

(2009) A. Dejgaard et al.   DIABETOLOGIA

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

(2009) H. M. Colhoun et al.   DIABETOLOGIA

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

(2009) C. J. Currie et al.   DIABETOLOGIA

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

(2009) L. G. Hemkens et al.   DIABETOLOGIA

The rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetes*

(2008) R. Krones et al.   DIABETES OBESITY & METABOLISM

Insulin analogues: an example of applied medical science

(2008) B. Sheldon et al.   DIABETES OBESITY & METABOLISM

A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period

(2008) Stephen Luzio et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

The Pharmacokinetic and Pharmacodynamic Properties of Different Formulations of Biphasic Insulin Aspart: A Randomized, Glucose Clamp, Crossover Study

(2008) T. Heise et al.   Diabetes Technology & Therapeutics

Absorption kinetics of insulin after subcutaneous administration

(2008) Tue Søeborg et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES